Major Objectives Behind This Study:
# To define, describe, and forecast the global apheresis market by product, technology, application, procedure, end user, and region.
# To provide detailed information about the factors influencing the market growth (drivers, restraints, opportunities, and challenges).
# To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market.
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
# To forecast the size of the apheresis market in five regions (along with major countries)—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
# To profile key players in the apheresis market and comprehensively analyze their core competencies and market shares.
# To track and analyze competitive developments such as acquisitions; new product launches; collaborations, partnerships, and agreements; and R&D activities of the leading players in the global apheresis market.
Recent Developments in the Global Apheresis Market:
# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.
# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.
# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.
# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.
Download PDF Brochure@
Major Growth Influencing Factors:
The market for apheresis is primarily driven by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns regarding blood safety, the increase in the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures.
However, the high cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of awareness, and the stringent donor recruitment criteria are factors expected to limit market growth to a certain extent in the coming years.
In 2018, the blood collection centers and blood component providers segment accounted for the largest share of the market.
Based on end users, the apheresis market is segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2018, the blood collection centers and blood component providers segment accounted for the largest share of 67.5% of the global apheresis market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, a growing number of blood centers, and increasing awareness of blood collection.
Geographical Growth Scenariio:
North America accounted for the largest share of the apheresis market in 2018
The apheresis market is segmented into five major regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the apheresis market. The large share of this region can be attributed to easier access to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.
Expected Revenue Gains:
The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.
Request Sample Pages@
Key Market Players
The key players in the global apheresis market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), and Nikkiso Co., Ltd. (Japan).